vs
Aurinia Pharmaceuticals Inc.（AUPH）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Aurinia Pharmaceuticals Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.1倍（$77.1M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 273.4%，领先110.7%），Aurinia Pharmaceuticals Inc.同比增速更快（28.8% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 23.8%）
Aurinia Pharmaceuticals是一家生物制药企业，专注于自身免疫疾病及肾脏疾病靶向疗法的研发与商业化，核心获批产品为用于治疗成人活动性狼疮性肾炎的Lupkynis，主要市场覆盖北美及欧洲地区。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
AUPH vs RIGL — 直观对比
营收规模更大
AUPH
是对方的1.1倍
$69.8M
营收增速更快
AUPH
高出7.6%
21.2%
净利率更高
RIGL
高出110.7%
273.4%
两年增速更快
RIGL
近两年复合增速
23.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.1M | $69.8M |
| 净利润 | $210.8M | $268.1M |
| 毛利率 | 88.6% | 91.5% |
| 营业利润率 | 43.1% | 33.2% |
| 净利率 | 273.4% | 384.0% |
| 营收同比 | 28.8% | 21.2% |
| 净利润同比 | 14651.2% | 1769.2% |
| 每股收益（稀释后） | $1.52 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AUPHRIGL
| Q4 25 | $77.1M | $69.8M | ||
| Q3 25 | $73.5M | $69.5M | ||
| Q2 25 | $70.0M | $101.7M | ||
| Q1 25 | $62.5M | $53.3M | ||
| Q4 24 | $59.9M | $57.6M | ||
| Q3 24 | $67.8M | $55.3M | ||
| Q2 24 | $57.2M | $36.8M | ||
| Q1 24 | $50.3M | $29.5M |
净利润AUPHRIGL
| Q4 25 | $210.8M | $268.1M | ||
| Q3 25 | $31.6M | $27.9M | ||
| Q2 25 | $21.5M | $59.6M | ||
| Q1 25 | $23.3M | $11.4M | ||
| Q4 24 | $1.4M | $14.3M | ||
| Q3 24 | $14.3M | $12.4M | ||
| Q2 24 | $722.0K | $-1.0M | ||
| Q1 24 | $-10.7M | $-8.2M |
毛利率AUPHRIGL
| Q4 25 | 88.6% | 91.5% | ||
| Q3 25 | 88.9% | 93.2% | ||
| Q2 25 | 89.8% | 95.6% | ||
| Q1 25 | 86.3% | 91.7% | ||
| Q4 24 | 90.7% | 89.9% | ||
| Q3 24 | 91.1% | 85.5% | ||
| Q2 24 | 84.4% | 92.4% | ||
| Q1 24 | 84.6% | 93.1% |
营业利润率AUPHRIGL
| Q4 25 | 43.1% | 33.2% | ||
| Q3 25 | 40.5% | 40.9% | ||
| Q2 25 | 28.7% | 60.1% | ||
| Q1 25 | 35.0% | 23.9% | ||
| Q4 24 | -2.8% | 28.9% | ||
| Q3 24 | 17.3% | 25.4% | ||
| Q2 24 | -2.6% | 1.2% | ||
| Q1 24 | -26.3% | -23.6% |
净利率AUPHRIGL
| Q4 25 | 273.4% | 384.0% | ||
| Q3 25 | 42.9% | 40.2% | ||
| Q2 25 | 30.7% | 58.6% | ||
| Q1 25 | 37.4% | 21.5% | ||
| Q4 24 | 2.4% | 24.9% | ||
| Q3 24 | 21.2% | 22.5% | ||
| Q2 24 | 1.3% | -2.8% | ||
| Q1 24 | -21.4% | -27.9% |
每股收益（稀释后）AUPHRIGL
| Q4 25 | $1.52 | $14.11 | ||
| Q3 25 | $0.23 | $1.46 | ||
| Q2 25 | $0.16 | $3.28 | ||
| Q1 25 | $0.16 | $0.63 | ||
| Q4 24 | $0.00 | $0.82 | ||
| Q3 24 | $0.10 | $0.70 | ||
| Q2 24 | $0.01 | $-0.06 | ||
| Q1 24 | $-0.07 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.2M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $581.3M | $391.5M |
| 总资产 | $751.6M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资AUPHRIGL
| Q4 25 | $80.2M | $155.0M | ||
| Q3 25 | $72.9M | $137.1M | ||
| Q2 25 | $52.9M | $108.4M | ||
| Q1 25 | $66.1M | $77.1M | ||
| Q4 24 | $83.4M | $77.3M | ||
| Q3 24 | $36.6M | $61.1M | ||
| Q2 24 | $33.3M | $49.1M | ||
| Q1 24 | $63.9M | $49.5M |
总债务AUPHRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益AUPHRIGL
| Q4 25 | $581.3M | $391.5M | ||
| Q3 25 | $365.8M | $117.6M | ||
| Q2 25 | $335.3M | $81.9M | ||
| Q1 25 | $350.2M | $18.6M | ||
| Q4 24 | $377.5M | $3.3M | ||
| Q3 24 | $388.0M | $-14.6M | ||
| Q2 24 | $364.6M | $-29.9M | ||
| Q1 24 | $359.5M | $-31.7M |
总资产AUPHRIGL
| Q4 25 | $751.6M | $513.6M | ||
| Q3 25 | $527.5M | $242.5M | ||
| Q2 25 | $502.6M | $206.7M | ||
| Q1 25 | $504.9M | $176.0M | ||
| Q4 24 | $550.6M | $164.0M | ||
| Q3 24 | $549.4M | $139.4M | ||
| Q2 24 | $523.5M | $128.4M | ||
| Q1 24 | $516.6M | $126.5M |
负债/权益比AUPHRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.7M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 0.22× | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AUPHRIGL
| Q4 25 | $45.7M | $22.0M | ||
| Q3 25 | $44.4M | $24.0M | ||
| Q2 25 | $44.2M | $30.5M | ||
| Q1 25 | $1.3M | $-893.0K | ||
| Q4 24 | $30.1M | $14.5M | ||
| Q3 24 | $17.0M | $21.7M | ||
| Q2 24 | $15.8M | $302.0K | ||
| Q1 24 | $-18.6M | $-5.0M |
现金转化率AUPHRIGL
| Q4 25 | 0.22× | 0.08× | ||
| Q3 25 | 1.41× | 0.86× | ||
| Q2 25 | 2.06× | 0.51× | ||
| Q1 25 | 0.06× | -0.08× | ||
| Q4 24 | 21.07× | 1.01× | ||
| Q3 24 | 1.19× | 1.75× | ||
| Q2 24 | 21.94× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AUPH
| Products | $74.2M | 96% |
| License Collaboration And Royalty Revenue | $2.9M | 4% |
RIGL
暂无分部数据
